NPPA fixes retail price of 25 formulations

New Delhi, March 31, 2023 :

 

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 25 formulations under the Drugs (Prices Control) Order, 2013, based on the recently held Authority meeting.

The list includes several anti-diabetic formulations with dapagliflozin combination, along with blood pressure lowering drugs and others.

Retail prices of itraconazole capsules (supra-bio available formulation) 130 mg from Abbott Healthcare has been fixed at Rs. 20.72, camylofin dihydrochloride 50 mg and paracetamol IP 325 mg tablets from Abbott Healthcare at Rs. 5.53 per unit, telmisartan 40 mg and chlorthalidone 6.25 mg tablets at Rs. 8.04, glimepiride IP 4 mg tablets and 3 mg tablets from German Remedies at Rs. 11.57 and Rs. 9.77 respectively, gliclazide IP 30 mg modified release and metformin hydrochloride IP 500 mg extended release tablets from Servier India Pvt Ltd, bilastine 20 mg and montelukast 10 mg orodispersible tablets from Sun Pharmaceuticals Industries at Rs. 13.21 per unit, among others.

The drug price regulator has also fixed the prices of various formulations of dapagliflozin and metformin hydrochloride extended release from Alembic Pharmaceuticals and Mankind Prime Labs, through the order.

Price of a combination of clarithromycin, esomeprazole and amoxicillin tablets, in a combi pack of six tablets, from Zuventus Healthcare Ltd has also been fixed at Rs. 152.17 per combi pack.

Bisoprolol fumarate and amlodipine besylate combination from Cipla, erythropoietin Injection BP 6000 IU/ml from Wockhardt Ltd, glycopyrronium Ph.Eur with formoterol fumarate IP and budesonide inhalation powder from Lupin Ltd, bisoprolol fumarate and amlodipine combination tablet from Zydus Healthcare, cilnidipine and telmisartan combination from Glenmark Pharmaceuticals are some of the formulations for which the retail prices has been announced by the NPPA now.

The manufacturers of these drugs may add Goods and Services Tax (GST) only if they have paid actually or it is payable to the government on the retail price mentioned in the order. The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified in the Order and the manufacturer shall issue a price list in Form-V from the date of notification as per the DPCO, 2013 to NPPA and submit a copy of the same to the State Drug Controller and dealers.

Based on the DPCO, 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same, said the Authority.

In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified in the order, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, it added. Pharmabiz